LOG IN
SIGN UP
MARKET
VIVO
VIVO
Meridian Bioscience Inc
NASDAQ
32.50
+0.51
+1.59%
After Hours: 32.50 0 0.00% 16:15 10/04 EDT
OPEN
32.07
PREV CLOSE
31.99
HIGH
32.72
LOW
32.07
VOLUME
520.88K
TURNOVER
0
52 WEEK HIGH
34.38
52 WEEK LOW
17.20
MARKET CAP
1.42B
P/E (TTM)
33.14
1D
5D
1M
3M
1Y
5Y
VIVO cannabis announces agreement to amend outstanding debentures
VIVO Cannabis (OTCQB:VVCIF) has announced agreement for outstanding unsecured convertible debentures. <li...
Seekingalpha · 09/19 13:05
Here's when Meridian Bioscience investors will vote on firm's $1.53B acquisition
Meridian Bioscience has set a date for its shareholders to vote on a $1.53 billion acquisition deal involving two South Korea-based firms.
American City Business Journals · 09/12 17:19
Looking Into Meridian Bioscience's Return On Capital Employed
Meridian Bioscience (NASDAQ:VIVO) brought in sales totaling $67.77 million during Q3 according to data provided by Benzinga Pro. However, earnings decreased 125.52%, resulting in a loss of $7.34 million.
Benzinga · 08/26 14:33
Meridian Bioscience (VIVO) Meets Q3 Earnings Estimates
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 0% and 1.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 13:25
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Meridian Bioscience press release (<span class="ticker-hover-wrapp...
Seekingalpha · 08/05 12:47
Meridian Bioscience: Q3 Earnings Insights
Meridian Bioscience (NASDAQ:VIVO) reported its Q3 earnings results on Friday, August 5, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Benzinga · 08/05 12:30
BRIEF-Meridian Bioscience Inc Reports Q3 Net Loss Per Basic Common Share Of $0.17
BRIEF-Meridian Bioscience Inc Reports Q3 Net Loss Per Basic Common Share Of $0.17
Reuters · 08/05 12:22
Meridian Bioscience Q3 EPS $0.16, Inline, Sales $67.80M Beat $66.82M Estimate
Meridian Bioscience (NASDAQ:VIVO) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 27.27 percent decrease over earnings of $0.22 per share from the same period last year.
Benzinga · 08/05 12:14
About VIVO
Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal and respiratory infectious diseases and elevated blood lead levels. The Company's segments include Diagnostics and Life Science. The Diagnostics segment consists of manufacturing operations for infectious disease products in Cincinnati, Ohio; Quebec City, Canada; and Modi' in, Israel. The segment also includes blood chemistry products in Billerica, Massachusetts and the sale and distribution of diagnostics products domestically and abroad. The Life Science segment consists of manufacturing operations in Memphis, Tennessee; Boca Raton, Florida; London, England; and Luckenwalde, Germany; and the sale and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, and bioresearch reagents domestically and abroad.
Webull offers kinds of Meridian Bioscience, Inc. stock information, including NASDAQ:VIVO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIVO stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading VIVO stock methods without spending real money on the virtual paper trading platform.